The best science demands the best people—and at BioAgilytix’s Boston lab, there’s no shortage of skilled and dedicated scientists. I’m particularly proud to be working...
The increasing complexity of large molecule development, along with the rise of personalized medicine, is driving more need for sponsors to place their large molecule...
In our recruitment process we are often asked the question, “what’s a day in the life like at a CRO?” Many of our applicants are coming from a pharma or biotech...
Pre-existing antibodies against the adeno-associated virus (AAV) are a known challenge in gene therapy programs that use AAV-based viral vectors as their mode of gene...
Every BioAgilytix team member brings unique value to the table to benefit our customers. Their combined experience working with large molecule drug modalities is of...
The 14th WRIB Virtual meeting kicked off this week, and I’m excited to be joining the event for the first time as Chief Commercial Officer of BioAgilytix. WRIB marks a...
BioAgilytix’s Hamburg, Germany lab is renowned for many reasons, from being involved in some of the very first cases of immunogenicity testing to being one of the...
Gene editing offers the potential to correct DNA mutations to treat or eliminate human diseases by changing the DNA of cells with single base pair precision....
Originally published September 12, 2018. Click here to see an update on the study.
As a member of the BioAgilytix team, I have the opportunity to the support...